公开(公告)号：US10822408B2

公开(公告)日：2020-11-03

申请号：US16063152

申请日：2016-12-15

Applicant: AMGEN INC.

Inventor： Agnes E. Hamburger ,  Cen Xu ,  Hong Sun ,  Yuan D. Shih ,  Dohan Weeraratne

IPC: A61K39/395 ,  C07K16/26 ,  A61P25/06 ,  C07K16/42 ,  A61K39/00 ,  A61K9/00

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

公开(公告)号：US20190256607A1

公开(公告)日：2019-08-22

申请号：US16287533

申请日：2019-02-27

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: C07K16/28

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

公开(公告)号：US10259877B2

公开(公告)日：2019-04-16

申请号：US15136736

申请日：2016-04-22

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: A61K39/00 ,  C07K16/28

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

公开(公告)号：US11780914B2

公开(公告)日：2023-10-10

申请号：US17031674

申请日：2020-09-24

Applicant: AMGEN INC.

Inventor： Agnes E. Hamburger ,  Cen Xu ,  Hong Sun ,  Yuan D. Shih ,  Dohan Weeraratne

IPC: A61K39/395 ,  C07K16/26 ,  C12N15/13 ,  A61P25/06 ,  C07K16/42 ,  A61K39/00 ,  A61K9/00

CPC classification number: C07K16/26 ,  A61P25/06 ,  C07K16/4283 ,  A61K9/0019 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

公开(公告)号：US11466090B2

公开(公告)日：2022-10-11

申请号：US16287533

申请日：2019-02-27

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.